Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Preclinical assessment of an antibody-PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells.

Kinneer K, Flynn M, Thomas SB, Meekin J, Varkey R, Xiao X, Zhong H, Breen S, Hynes PG, Fleming R, Bezabeh B, Chen CT, Wetzel L, Chen R, Dimasi N, Tai YT, Anderson KC, Herbst R, Howard PW, Hurt EM, Tice DA.

Leukemia. 2019 Mar;33(3):766-771. doi: 10.1038/s41375-018-0278-7. Epub 2018 Oct 12. No abstract available.

PMID:
30315237
2.

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression.

Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, Szeliga W, Herbst R, Harms PW, Fecher LA, Vats P, Chinnaiyan AM, Lao CD, Lawrence TS, Wicha M, Hamanishi J, Mandai M, Kryczek I, Zou W.

J Clin Invest. 2018 Apr 2;128(4):1708. doi: 10.1172/JCI120803. Epub 2018 Apr 2. No abstract available.

3.

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression.

Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, Szeliga W, Herbst R, Harms PW, Fecher LA, Vats P, Chinnaiyan AM, Lao CD, Lawrence TS, Wicha M, Hamanishi J, Mandai M, Kryczek I, Zou W.

J Clin Invest. 2018 Feb 1;128(2):805-815. doi: 10.1172/JCI96113. Epub 2018 Jan 16. Erratum in: J Clin Invest. 2018 Apr 2;128(4):1708.

4.

Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4.

Harper J, Lloyd C, Dimasi N, Toader D, Marwood R, Lewis L, Bannister D, Jovanovic J, Fleming R, D'Hooge F, Mao S, Marrero AM, Korade M 3rd, Strout P, Xu L, Chen C, Wetzel L, Breen S, van Vlerken-Ysla L, Jalla S, Rebelatto M, Zhong H, Hurt EM, Hinrichs MJ, Huang K, Howard PW, Tice DA, Hollingsworth RE, Herbst R, Kamal A.

Mol Cancer Ther. 2017 Aug;16(8):1576-1587. doi: 10.1158/1535-7163.MCT-16-0825. Epub 2017 May 18.

5.

5T4-Targeted Therapy Ablates Cancer Stem Cells and Prevents Recurrence of Head and Neck Squamous Cell Carcinoma.

Kerk SA, Finkel KA, Pearson AT, Warner KA, Zhang Z, Nör F, Wagner VP, Vargas PA, Wicha MS, Hurt EM, Hollingsworth RE, Tice DA, Nör JE.

Clin Cancer Res. 2017 May 15;23(10):2516-2527. doi: 10.1158/1078-0432.CCR-16-1834. Epub 2016 Oct 25.

6.

IL-6 Inhibition With MEDI5117 Decreases The Fraction of Head and Neck Cancer Stem Cells and Prevents Tumor Recurrence.

Finkel KA, Warner KA, Kerk S, Bradford CR, McLean SA, Prince ME, Zhong H, Hurt EM, Hollingsworth RE, Wicha MS, Tice DA, Nör JE.

Neoplasia. 2016 May;18(5):273-281. doi: 10.1016/j.neo.2016.03.004. Epub 2016 Apr 15.

7.

Will cancer stem cells provide more effective biomarkers?

Hurt EM.

Front Biosci (Elite Ed). 2016 Jan 1;8:181-8. Review.

PMID:
26709654
8.

Cancer stem cell plasticity and tumor hierarchy.

Cabrera MC, Hollingsworth RE, Hurt EM.

World J Stem Cells. 2015 Jan 26;7(1):27-36. doi: 10.4252/wjsc.v7.i1.27. Review.

9.

Genomic Analysis of Invasive Human Bone Marrow Derived Mesenchymal Stem Cells.

Mathews LA, Hurt EM, Zhang X, Farrar WL.

J Bone Marrow Res. 2013 May 23;1:122.

10.

EZH2 is required for breast and pancreatic cancer stem cell maintenance and can be used as a functional cancer stem cell reporter.

van Vlerken LE, Kiefer CM, Morehouse C, Li Y, Groves C, Wilson SD, Yao Y, Hollingsworth RE, Hurt EM.

Stem Cells Transl Med. 2013 Jan;2(1):43-52. doi: 10.5966/sctm.2012-0036. Epub 2012 Dec 27.

11.

The role of epigenetic regulation in stem cell and cancer biology.

van Vlerken LE, Hurt EM, Hollingsworth RE.

J Mol Med (Berl). 2012 Jul;90(7):791-801. doi: 10.1007/s00109-012-0917-9. Epub 2012 Jun 2. Review.

PMID:
22660276
12.

Long-term recovery of irradiated prostate cancer increases cancer stem cells.

Cho YM, Kim YS, Kang MJ, Farrar WL, Hurt EM.

Prostate. 2012 Dec 1;72(16):1746-56. doi: 10.1002/pros.22527. Epub 2012 Apr 18.

PMID:
22513891
13.

The role of upregulated miRNAs and the identification of novel mRNA targets in prostatospheres.

Cabarcas SM, Thomas S, Zhang X, Cherry JM, Sebastian T, Yerramilli S, Lader E, Farrar WL, Hurt EM.

Genomics. 2012 Feb;99(2):108-17. doi: 10.1016/j.ygeno.2011.11.007. Epub 2011 Dec 20.

14.

Increased expression of DNA repair genes in invasive human pancreatic cancer cells.

Mathews LA, Cabarcas SM, Hurt EM, Zhang X, Jaffee EM, Farrar WL.

Pancreas. 2011 Jul;40(5):730-9. doi: 10.1097/MPA.0b013e31821ae25b.

15.

Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer.

Crea F, Hurt EM, Mathews LA, Cabarcas SM, Sun L, Marquez VE, Danesi R, Farrar WL.

Mol Cancer. 2011 Apr 18;10:40. doi: 10.1186/1476-4598-10-40.

16.

A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression.

Annunziata CM, Hernandez L, Davis RE, Zingone A, Lamy L, Lam LT, Hurt EM, Shaffer AL, Kuehl WM, Staudt LM.

Blood. 2011 Feb 24;117(8):2396-404. doi: 10.1182/blood-2010-04-278788. Epub 2010 Dec 16.

17.

Defining the molecular nexus of cancer, type 2 diabetes and cardiovascular disease.

Cabarcas SM, Hurt EM, Farrar WL.

Curr Mol Med. 2010 Nov;10(8):744-55. Review.

18.

Epigenetic regulation of CpG promoter methylation in invasive prostate cancer cells.

Mathews LA, Hurt EM, Zhang X, Farrar WL.

Mol Cancer. 2010 Oct 7;9:267. doi: 10.1186/1476-4598-9-267.

19.

Clinical significance of Polycomb gene expression in brain tumors.

Crea F, Hurt EM, Farrar WL.

Mol Cancer. 2010 Sep 30;9:265. doi: 10.1186/1476-4598-9-265.

20.

BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer.

Crea F, Duhagon Serrat MA, Hurt EM, Thomas SB, Danesi R, Farrar WL.

Int J Cancer. 2011 Apr 15;128(8):1946-54. doi: 10.1002/ijc.25522.

21.

Genomic profiling of tumor initiating prostatospheres.

Duhagon MA, Hurt EM, Sotelo-Silveira JR, Zhang X, Farrar WL.

BMC Genomics. 2010 May 25;11:324. doi: 10.1186/1471-2164-11-324.

22.

Gossypol induces apoptosis by activating p53 in prostate cancer cells and prostate tumor-initiating cells.

Volate SR, Kawasaki BT, Hurt EM, Milner JA, Kim YS, White J, Farrar WL.

Mol Cancer Ther. 2010 Feb;9(2):461-70. doi: 10.1158/1535-7163.MCT-09-0507. Epub 2010 Feb 2.

23.

Identification of vitronectin as an extrinsic inducer of cancer stem cell differentiation and tumor formation.

Hurt EM, Chan K, Serrat MA, Thomas SB, Veenstra TD, Farrar WL.

Stem Cells. 2010 Mar 31;28(3):390-8. doi: 10.1002/stem.271.

24.

Targeting prostate cancer stem cells.

Crea F, Mathews LA, Farrar WL, Hurt EM.

Anticancer Agents Med Chem. 2009 Dec;9(10):1105-13. Review.

PMID:
19925394
25.

Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature.

Klarmann GJ, Hurt EM, Mathews LA, Zhang X, Duhagon MA, Mistree T, Thomas SB, Farrar WL.

Clin Exp Metastasis. 2009;26(5):433-46. doi: 10.1007/s10585-009-9242-2. Epub 2009 Feb 17.

26.

Effects of the sesquiterpene lactone parthenolide on prostate tumor-initiating cells: An integrated molecular profiling approach.

Kawasaki BT, Hurt EM, Kalathur M, Duhagon MA, Milner JA, Kim YS, Farrar WL.

Prostate. 2009 Jun 1;69(8):827-37. doi: 10.1002/pros.20931.

27.

Targeting cancer stem cells with phytochemicals.

Kawasaki BT, Hurt EM, Mistree T, Farrar WL.

Mol Interv. 2008 Aug;8(4):174-84. doi: 10.1124/mi.8.4.9. Review.

PMID:
18829843
28.

Activation of signal transducer and activator of transcription 3 through a phosphomimetic serine 727 promotes prostate tumorigenesis independent of tyrosine 705 phosphorylation.

Qin HR, Kim HJ, Kim JY, Hurt EM, Klarmann GJ, Kawasaki BT, Duhagon Serrat MA, Farrar WL.

Cancer Res. 2008 Oct 1;68(19):7736-41. doi: 10.1158/0008-5472.CAN-08-1125.

29.

Effects of manganese superoxide dismutase silencing on androgen receptor function and gene regulation: implications for castration-resistant prostate cancer.

Sharifi N, Hurt EM, Thomas SB, Farrar WL.

Clin Cancer Res. 2008 Oct 1;14(19):6073-80. doi: 10.1158/1078-0432.CCR-08-0591.

30.

Cancer stem cells: the seeds of metastasis?

Hurt EM, Farrar WL.

Mol Interv. 2008 Jun;8(3):140-2. doi: 10.1124/mi.8.3.7. No abstract available.

PMID:
18693193
31.

Expression of the ZEB1 (deltaEF1) transcription factor in human: additional insights.

Hurt EM, Saykally JN, Anose BM, Kalli KR, Sanders MM.

Mol Cell Biochem. 2008 Nov;318(1-2):89-99. doi: 10.1007/s11010-008-9860-z. Epub 2008 Jul 12.

PMID:
18622689
32.

CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis.

Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL.

Br J Cancer. 2008 Feb 26;98(4):756-65. doi: 10.1038/sj.bjc.6604242. Epub 2008 Feb 12.

33.

Androgen receptor expression in prostate cancer stem cells: is there a conundrum?

Sharifi N, Hurt EM, Farrar WL.

Cancer Chemother Pharmacol. 2008 Oct;62(5):921-3. Epub 2007 Dec 13.

PMID:
18075739
34.

DNA hypermethylation and partial gene silencing of human thymine- DNA glycosylase in multiple myeloma cell lines.

Peng B, Hurt EM, Hodge DR, Thomas SB, Farrar WL.

Epigenetics. 2006 Jul-Sep;1(3):138-45. Epub 2006 May 25.

PMID:
17965616
35.

Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells.

Kawasaki BT, Mistree T, Hurt EM, Kalathur M, Farrar WL.

Biochem Biophys Res Commun. 2007 Dec 28;364(4):778-82. Epub 2007 Oct 25.

36.

Molecular consequences of SOD2 expression in epigenetically silenced pancreatic carcinoma cell lines.

Hurt EM, Thomas SB, Peng B, Farrar WL.

Br J Cancer. 2007 Oct 22;97(8):1116-23. Epub 2007 Sep 25.

37.

Functional and genomic analyses of FOXP3-transduced Jurkat-T cells as regulatory T (Treg)-like cells.

Kim JY, Kim HJ, Hurt EM, Chen X, Howard OMZ, Farrar WL.

Biochem Biophys Res Commun. 2007 Oct 12;362(1):44-50. doi: 10.1016/j.bbrc.2007.07.187. Epub 2007 Aug 10.

PMID:
17706604
38.

Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.

Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, Dave S, Hurt EM, Tan B, Zhao H, Stephens O, Santra M, Williams DR, Dang L, Barlogie B, Shaughnessy JD Jr, Kuehl WM, Staudt LM.

Cancer Cell. 2007 Aug;12(2):115-30.

39.

TGFBR3 loss and consequences in prostate cancer.

Sharifi N, Hurt EM, Kawasaki BT, Farrar WL.

Prostate. 2007 Feb 15;67(3):301-11.

PMID:
17192875
40.

Integrated molecular profiling of SOD2 expression in multiple myeloma.

Hurt EM, Thomas SB, Peng B, Farrar WL.

Blood. 2007 May 1;109(9):3953-62. Epub 2006 Dec 27.

41.

Stem cells in prostate cancer: resolving the castrate-resistant conundrum and implications for hormonal therapy.

Sharifi N, Kawasaki BT, Hurt EM, Farrar WL.

Cancer Biol Ther. 2006 Aug;5(8):901-6. Epub 2006 Aug 28. Review.

PMID:
16855379
42.

Reversal of p53 epigenetic silencing in multiple myeloma permits apoptosis by a p53 activator.

Hurt EM, Thomas SB, Peng B, Farrar WL.

Cancer Biol Ther. 2006 Sep;5(9):1154-60. Epub 2006 Sep 6.

PMID:
16855375
43.

The role of IL-6 and STAT3 in inflammation and cancer.

Hodge DR, Hurt EM, Farrar WL.

Eur J Cancer. 2005 Nov;41(16):2502-12. Epub 2005 Sep 30. Review.

PMID:
16199153
44.

Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation.

Hodge DR, Peng B, Cherry JC, Hurt EM, Fox SD, Kelley JA, Munroe DJ, Farrar WL.

Cancer Res. 2005 Jun 1;65(11):4673-82.

45.

XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation.

Shaffer AL, Shapiro-Shelef M, Iwakoshi NN, Lee AH, Qian SB, Zhao H, Yu X, Yang L, Tan BK, Rosenwald A, Hurt EM, Petroulakis E, Sonenberg N, Yewdell JW, Calame K, Glimcher LH, Staudt LM.

Immunity. 2004 Jul;21(1):81-93.

46.

Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma.

Hurt EM, Wiestner A, Rosenwald A, Shaffer AL, Campo E, Grogan T, Bergsagel PL, Kuehl WM, Staudt LM.

Cancer Cell. 2004 Feb;5(2):191-9.

47.

The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma.

Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, Gascoyne RD, Grogan TM, Muller-Hermelink HK, Smeland EB, Chiorazzi M, Giltnane JM, Hurt EM, Zhao H, Averett L, Henrickson S, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Montserrat E, Bosch F, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Fisher RI, Miller TP, LeBlanc M, Ott G, Kvaloy S, Holte H, Delabie J, Staudt LM.

Cancer Cell. 2003 Feb;3(2):185-97.

48.

Analysis of gamma c-family cytokine target genes. Identification of dual-specificity phosphatase 5 (DUSP5) as a regulator of mitogen-activated protein kinase activity in interleukin-2 signaling.

Kovanen PE, Rosenwald A, Fu J, Hurt EM, Lam LT, Giltnane JM, Wright G, Staudt LM, Leonard WJ.

J Biol Chem. 2003 Feb 14;278(7):5205-13. Epub 2002 Nov 14.

49.

Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program.

Shaffer AL, Lin KI, Kuo TC, Yu X, Hurt EM, Rosenwald A, Giltnane JM, Yang L, Zhao H, Calame K, Staudt LM.

Immunity. 2002 Jul;17(1):51-62.

50.

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, López-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM; Lymphoma/Leukemia Molecular Profiling Project.

N Engl J Med. 2002 Jun 20;346(25):1937-47.

Supplemental Content

Support Center